Stockholm 31st of January 2024 - Alder Therapeutics was recently granted a meeting with the European Medicine's Agency's (EMA) Innovation Task Force (ITF).
These highly sought after meetings provide developers a forum for early dialogue on innovative medicines and give an opportunity to discuss development plans with the EMA’s innovation experts.
The meeting provided many positive insights and feedback into Alder Therapeutics' development plans for ALD01 and ALD02 - both of which also recently received ATMP classification from EMA’s Committee for Advanced Therapies (CAT) as tissue engineered products.
Alder Therapeutics is a virtual pre-clinical replacement cell therapy development company that is shaping the future of regenerative medicine. Founded in 2022 by seasoned cell therapy and industry experts, the company has two promising allogeneic stem cell therapy programs in the pipeline: one for degenerative eye diseases, and one for chronic heart disease. At the core of the company’s success is the AlderEdge™ platform — a novel approach to cell therapy development that keeps the commercial product in mind from the start for a de-risked route to success.
Kristian Tryggvason
CEO
Alder Therapeutics
kristian@aldertx.com
Want to support us on our journey to shape the future of regenerative medicine?
